Johnson & Johnson (JNJ) Tops Q2 EPS by 4c; Maintains Operational Guidance at Midpoint, Cuts on Reported Basis

Johnson & Johnson (NYSE: JNJ) reported Q2 EPS of $2.59, $0.04 better than the analyst estimate of $2.55. Revenue for the quarter came in at $24 billion versus the consensus estimate of $23.8 billion.

GUIDANCE:

Company maintaining 2022 full-year guidance at midpoints for adjusted operational sales and adjusted operational earnings per share; strengthening U.S. dollar impacting estimate for reported results.

Sees Adjusted Operational EPS of $10.65-$10.75, versus prior of $10.60-$10.80. Sees Adjusted EPS of $10.00-$10.10, versus prior of $10.15-$10.35.

Sees Operational Sales of $97.3-$98.3 billion, in-line with prior view. Sees Estimated Reported Sales of $93.3-$94.3 billion, versus prior of $94.8-$95.8 billion.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• InspireMD (NSPR) Tops Q2 EPS by 1c
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c